Fundraising FoxCellerant Therapeutics
San Carlos, US · Delaware corporation
Find your way into Cellerant Therapeutics
Sign up to find every way you can get introduced to Cellerant Therapeutics
- Your email: who you already know at Cellerant Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cellerant Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
RM
Ramkumar MandalamExecutive
SG
Stephen GreenbergNamed on SEC filing
GS
Gisela SchwabNamed on SEC filing
RY
Rodney YoungNamed on SEC filing
RG
Richard G. RathmannNamed on SEC filing
RH
Robby HogleNamed on SEC filing
Board
RC
Richard ChyetteBoard director
LS
Lowell SearsBoard director
Reported raises · per SEC filings
Form D private placements$8.7M disclosed across 2 rounds · 2014–2016
▶$6.5MraisedFeb 2019 · 10 investors · BiotechnologyRule 506(c)
▶$6.5MraisedFeb 2019 · 10 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Stephen GreenbergDirector
- Gisela SchwabDirector
- Rodney YoungExecutive Officer
- Richard G. RathmannDirector
- Ramkumar MandalamExecutive Officer, Director
- Robby HogleDirector
- Offering amount
- $10M
- Amount sold
- $6.5M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2.2MraisedJan 2014 · 5 investors · BiotechnologyRule 506(c)
▶$2.2MraisedJan 2014 · 5 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Richard ChyetteDirector
- Ramkumar MandalamExecutive Officer, Director
- Lowell SearsDirector
- Stephen GreenbergDirector
- Richard G. RathmannDirector
- Gisela SchwabDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $223.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2013 | $200.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $194.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2007 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $296.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $804.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- How much funding has Cellerant Therapeutics raised?
- Cellerant Therapeutics has disclosed $8.7M raised across 2 rounds.
- Where is Cellerant Therapeutics headquartered?
- Cellerant Therapeutics is headquartered in San Carlos, US.